# Diphtheria-Measles-Rubella Webinar

2<sup>nd</sup> April 2025




### **Presentation outline**

- Global diphtheria cases
- Africa, South Africa status of diphtheria cases
- DTP vaccination coverage for WHO regions
- Diphtheria outbreak
- Preliminary diphtheria vulnerability mapping in the WHO African Region (November 2023)
- WHO guidance




### Global Diphtheria reported cases and incidence by year



Source: WHO Immunization Data portal

### Number of reported diphtheria cases in Who regions



Year	Global	Africa	South Africa
2023	24,782	18,684	17
2022	10,018	4,856	
2021	8,659	4,724	0
2020	10,137	5,387	9
2019	22,986	11,400	0
2018	16,911	1,971	4
2017	8,819	118	4
2016	7,102	2,870	0
2015	4,535	1,654	15

Source: WHO/UNICEF Joint Reporting Form on Immunization (JRF) https://immunizationdata.who.int/global/wiise-detail-page/diphtheria-reported-cases-and-incidence

Source: WHO Immunization Data portal World Health Organization, WHO, 2025, All rights reserved




### DTP vaccination coverage for WHO regions

Country / Region	Antigen	Data source	2024	2023	2022	2021	2020	2019	2018	2017	2016
	DTP-containing vaccine, 1st dose	WUENIC		83%	81%	81%	82%	83%	82%	81%	81%
African Region	DTP-containing vaccine 3rd dose	WUENIC		74%	73%	73%	74%	77%	75%	74%	73%
Eastern	DTP-containing vaccine, 1st dose	WUENIC		85%	87%	87%	86%	88%	88%	86%	85%
Mediterranean Region	DTP-containing vaccine, 3rd dose	WUENIC		79%	81%	80%	80%	84%	82%	81%	81%
European Region	DTP-containing vaccine, 1st dose	WUENIC		97%	97%	97%	97%	98%	97%	97%	96%
European Region	DTP-containing vaccine, 3rd dose	WUENIC		95%	95%	94%	94%	95%	95%	94%	92%
Region of the	DTP-containing vaccine, 1st dose	WUENIC		91%	90%	87%	88%	89%	92%	94%	96%
Americas	DTP-containing vaccine, 3rd dose	WUENIC		86%	83%	81%	81%	84%	88%	87%	91%
South-East Asia	DTP-containing vaccine, 1st dose	WUENIC		92%	94%	86%	88%	94%	93%	93%	92%
Region	DTP-containing vaccine, 3rd dose	WUENIC		90%	92%	83%	86%	91%	90%	90%	89%
Western Pacific	DTP-containing vaccine, 1st dose	WUENIC		94%	96%	94%	96%	97%	96%	97%	97%
Region	DTP-containing vaccine, 3rd dose	WUENIC		92%	95%	93%	95%	96%	95%	96%	97%

- Since the end of the COVID-19 pandemic, outbreaks of diphtheria have been reported in Nigeria, Niger, Chad, Guinea, South Africa, Mauritania, Gabon, Cameroon
  - >70% in children < 14 years of age</li>
  - 76% unvaccinated / partially vaccinated
- Contributing factors:
  - Declining routine immunisation coverage rates
  - Conflict and population displacement
  - Overcrowding



### DTP 3 coverage and number of diphtheria cases in SA



Accumulation of unvaccinated children increasing immunity gap

**Vorld Health** rganization

Source: WHO Immunization Data portal

### **Diphtheria Outbreak**

 A single laboratory-confirmed case of diphtheria should trigger a public health response. Two epidemiologically linked cases, of which at least one is laboratoryconfirmed, is considered an outbreak of diphtheria.

#### Factors observed to influence outbreaks:


- susceptible population (zero-dose (not vaccinated) and under-immunized children)
- change in biotype strain
- rapid urbanization (decreased hygiene and overcrowding)
- population movement increase (for example migration or refugee camps).



# Preliminary diphtheria vulnerability mapping in the WHO African Region (November 2023)

WHO conducted a diphtheria vulnerability mapping and prioritized countries taking into consideration the diphtheria risk, including

- active outbreaks with low vaccination coverage
- countries bordering an outbreak country and any
- countries with subnational 'hotspots'
- Tier 1. Emergency Response—active outbreaks, including ongoing diphtheria outbreaks, and low vaccination coverage: Guinea, Mauritania, Niger, Nigeria and South Africa.
- Tier 2. High priority readiness/"response mode"—very low coverage or likely multiple subnational hotspots with low coverage:
- Tier 3. Medium priority readiness—low vaccination coverage:.
- Tier 4. Preparedness:





### WHO guidance – 1

- Control of diphtheria is based on the
  - primary prevention of disease by ensuring high population immunity through vaccination and
  - **secondary prevention** of spread by the **rapid investigation** of close contacts to ensure prompt treatment (antibiotics) of those infected.
- Epidemiological surveillance ensuring early detection of diphtheria outbreaks should be in place, and all countries should have access to laboratory facilities for reliable identification of toxigenic C. diphtheriae.
- Adequate clinical management involves administering antibiotics and DAT to neutralize the toxin and reducing complications and mortality.
- Vaccination is key to preventing cases and outbreaks.



### WHO guidance – 2

- Implement infection prevention and control measures in health care settings.
- Effective coordination and community engagement are crucial for a successful response to the outbreak.
- For travellers going to areas with diphtheria outbreaks to be appropriately
  vaccinated in accordance with the national vaccination schedule. A booster
  dose is recommended if more than 5 years have elapsed since their last dose.

# Measles and rubella elimination in AFR

**WHO AFRO** 

**April 2025** 




### **Outline**

- Global situation and elimination verification status
- Regional goal
- Routine measles immunisation coverage
- African Regional goal
- Measles and rubella incidence in AFR
- Challenges and WHO guidance



### Measles case distribution by month WHO Region (2020-2025)






## Measles/rubella verification of elimination status Feb 2025

### Measles

Region	Member States	Verified	% Verified	Eliminate d	Endemic	Not classified
AFR	47	0	0	0	47	0
AMR	35	34	97	0	0	1
EMR	21	4	19	0	17	0
EUR	53	33	62	8	11	1
SEAR	11	4	36	0	7	0
WPR	27	6	22	13	8	0
GLOBA L	194	81	42	21	90	2

### Rubella

Region	Member States	Verified	% Verified	Eliminate d	Endemic	Not classified
AFR	47	0	0	0	47	0
AMR	35	34	97	0	0	1
EMR	21	4	19	0	17	0
EUR	53	49	92	0	0	4
SEAR	11	5	45	1	5	0
WPR	27	5	19	13	9	0
GLOBA L	194	97	50	14	78	5





# African Regional goal: ≥ 80% countries attain measles and rubella elimination by 2030



>95% MCV1 and MCV2 coverage at national and district levels



≥ 95% coverage in Supplemental Immunisation Activities



incidence of < 1 case / million population /year (excluding imported cases).





Achieve the surveillance performance targets:

≥ 80% districts investigating one or more suspected measles cases /year, a non measles febrile rash illness rate of ≥ 2 per 100 000 population at national level.



## Second dose of measles vaccine (MCV2) and rubella vaccine (RCV) introduction in Africa - Dec 2024






35 / 47
 countries
 introduced
 RCV in AFR



# Measles and rubella immunisation coverage. African Region. WUENIC. 2014 - 2023



- Overall, the region has not reached the vaccination coverage
- Gradual increase of MCV2 and RCV1



### **Periodic Supplemental Immunisation Activities**

- A total of 164.8 million children were vaccinated in 28 preventive campaigns and 6 outbreak response campaigns in the years 2023 and 2024
- SA SIA in 2023







### Measles surveillance performance in AFR. (2022 – 2024). Data Source: Case based surveillance system


Indicator	2022	2023	2024
Total <b>suspected measles</b> cases	114,347	125,957	147,564
Total lab specimens collected	73,457	77,998	95,588
Total confirmed rubella cases	4,319	4,805	14,340
Incidence of confirmed rubella per million population	3.6	4.0	11.4
Total <b>confirmed measles</b> cases	52,231	73,094	77,698
Incidence of confirmed measles per million population	51.3	60.3	71

# Incidence of confirmed measles/rubella in 2024. African Region.






# Rubella case distribution by month and WHO Region (2017-2025)



# Rubella case distribution by month and WHO Region (2023-2025)





	Top 10 countries <mark>(2024)</mark>							
	Country	RCV in RI	Cases	% of Total				
	South Africa	No	13506	87				
	Nigeria	No	534	3				
8	United Republic of Tanzania	2014	300	2				
	DR Congo	No	255	2				
	Others	-	248	2				
	Ethiopia	No	247	2				
	Chad	No	129	1				
	Madagascar	No	108	1				
	Malawi	2017	49	0				
	Gabon	No	40	0				
	Uganda	2019	35	0				



### Rubella cases: South Africa

#### **ELIMINATION STATUS: ENDEMIC**





Female

Unknown

Incidence



### Challenges contributing to measles/rubella outbreaks

- Chronically low routine immunisation coverage
- Vaccine stock-outs
- Humanitarian contexts with population displacements
- Delays in implementing periodic SIAs
- Failure to fund SIAs in middle-income countries
- Measles susceptibility in school age groups and older ages while periodic campaigns tend to be limited to under 5s



# **STRATEGIC PRIORITY 5 Outbreaks and Emergencies**

Objective: Ensure **outbreak preparedness** for timely detection and effective response to limit the spread of measles and rubella and reduce related morbidity and mortality.

### **Key Focus Areas:**

- Develop stronger linkages between measles and rubella elimination and control efforts and the International Health Regulations and related processes.
- Strengthen national and subnational capacity for outbreak preparedness and response in collaboration with other disease programmes.
- Harness the expertise of CSOs.
- Strengthen capacity for outbreak investigations to identify root causes of outbreaks and inform corrective actions to improve health systems and routine immunization programmes





### Conclusion

### Responding to outbreaks

- Interrupt measles virus transmission.
- Reduce measles morbidity, mortality, complications and sequelae.
- Identify root causes so that immunity gaps and/or system weaknesses can be addressed to reduce the risk of future outbreaks.



### THANK YOU



